TG Therap released FY2025 Q2 earnings on August 4 Pre-Market (EST), actual revenue USD 141.15 M (forecast USD 146.27 M), actual EPS USD 0.17 (forecast USD 0.2811)

Brief Summary

TG Therapeutics reported 2025 Q2 revenue of $1.41 billion and EPS of $0.17, both missing market expectations which were $1.46 billion and $0.2811, respectively.

Impact of The News

Financial Performance Overview

• Revenue: TG Therapeutics’ revenue for Q2 2025 was reported at $1.41 billion, missing the market expectation of $1.46 billion. This indicates a slight underperformance in revenue generation compared to what the market had anticipated.
• EPS: The earnings per share (EPS) came in at $0.17, which is significantly lower than the expected $0.2811. This suggests a weaker profitability position than the market consensus.

Business Context and Peer Comparison

• TG Therapeutics has shown a notable improvement in net income, with Q2 2025 net income increasing to $28.2 million from $6.9 million in the same quarter of the previous year, indicating substantial growth in profitability on a year-over-year basis Reuters+ 2.
• However, when compared to peer performances, such as Berkshire Hathaway which experienced a 59.24% decline in net profit year-over-year , TG Therapeutics’ profitability growth is relatively more positive, although the EPS miss still highlights potential challenges in cost management or operational efficiencies.

Business Status and Future Trends

• Revenue Composition: The revenue primarily came from ‘briumvi’ in the U.S., with significant growth from $72.6 million in the previous year to $138.8 million in the second quarter of 2025, showcasing a strong product performance in the market Reuters.
• Future Outlook: The company has raised its full-year revenue target for ‘briumvi’ in the U.S. to approximately $570 million to $575 million, indicating confidence in continued strong sales performance Reuters.
• The overall trend suggests that while the company faces challenges in meeting quarterly expectations, the growth in product-specific revenue could support long-term business development and profitability.

Conclusion

• Despite the missed expectations in Q2 2025, the strong year-over-year growth in profitability and the positive outlook for key products like ‘briumvi’ suggest potential for recovery and growth in subsequent quarters. However, maintaining cost controls and improving operational efficiencies will be crucial to meeting future market expectations.